These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 22906725)

  • 1. 7-Valent pneumococcal conjugate vaccine and otitis media: effectiveness of a 2-dose versus 3-dose primary series.
    Stoecker C; Hampton LM; Moore MR
    Vaccine; 2012 Sep; 30(44):6256-62. PubMed ID: 22906725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 7-Valent pneumococcal conjugate vaccine and lower respiratory tract infections: effectiveness of a 2-dose versus 3-dose primary series.
    Pelton SI; Weycker D; Klein JO; Strutton D; Ciuryla V; Oster G
    Vaccine; 2010 Feb; 28(6):1575-82. PubMed ID: 20003928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
    Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced physician claims for otitis media after implementation of pneumococcal conjugate vaccine program in the province of Quebec, Canada.
    Wals PD; Carbon M; Sévin E; Deceuninck G; Ouakki M
    Pediatr Infect Dis J; 2009 Sep; 28(9):e271-5. PubMed ID: 19710582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in pneumococcal disease prevention: 13-valent pneumococcal conjugate vaccine for infants and children.
    Paradiso PR
    Clin Infect Dis; 2011 May; 52(10):1241-7. PubMed ID: 21507921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of pneumococcal conjugate vaccine and of reduction of antibiotic use on nasopharyngeal carriage of nonsusceptible pneumococci in children with acute otitis media.
    Cohen R; Levy C; de La Rocque F; Gelbert N; Wollner A; Fritzell B; Bonnet E; Tetelboum R; Varon E
    Pediatr Infect Dis J; 2006 Nov; 25(11):1001-7. PubMed ID: 17072121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media.
    Cohen R; Levy C; Bingen E; Koskas M; Nave I; Varon E
    Pediatr Infect Dis J; 2012 Mar; 31(3):297-301. PubMed ID: 22330166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling the decline in pneumococcal acute otitis media following the introduction of pneumococcal conjugate vaccines in the US.
    Shea KM; Weycker D; Stevenson AE; Strutton DR; Pelton SI
    Vaccine; 2011 Oct; 29(45):8042-8. PubMed ID: 21871518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pneumococcal vaccination reduced the risk of acute otitis media: Cohort study.
    Hasegawa J; Mori M; Showa S; Matsushima A; Ohnishi H; Tsugawa T; Yoto Y; Tsutsumi H
    Pediatr Int; 2015 Aug; 57(4):582-5. PubMed ID: 25615843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media.
    Block SL; Hedrick J; Harrison CJ; Tyler R; Smith A; Findlay R; Keegan E
    Pediatr Infect Dis J; 2004 Sep; 23(9):829-33. PubMed ID: 15361721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of an alternative reduced-dose infant schedule and a second year catch-up schedule with 7-valent pneumococcal conjugate vaccine on pneumococcal carriage: a randomized controlled trial.
    Dagan R; Givon-Lavi N; Porat N; Greenberg D
    Vaccine; 2012 Jul; 30(34):5132-40. PubMed ID: 22683519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of pneumococcal conjugate vaccine on nasopharyngeal bacterial colonization during acute otitis media.
    Revai K; McCormick DP; Patel J; Grady JJ; Saeed K; Chonmaitree T
    Pediatrics; 2006 May; 117(5):1823-9. PubMed ID: 16651345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pneumococcal conjugate vaccination in children with recurrent acute otitis media: a therapeutic alternative?
    van Kempen MJ; Vermeiren JS; Vaneechoutte M; Claeys G; Veenhoven RH; Rijkers GT; Sanders EA; Dhooge IJ
    Int J Pediatr Otorhinolaryngol; 2006 Feb; 70(2):275-85. PubMed ID: 16140397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-effectiveness of pneumococcal conjugate vaccination in Australia.
    Butler JR; McIntyre P; MacIntyre CR; Gilmour R; Howarth AL; Sander B
    Vaccine; 2004 Mar; 22(9-10):1138-49. PubMed ID: 15003641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nasopharyngeal pneumococcal carriage after combined pneumococcal conjugate and polysaccharide vaccination in children with a history of recurrent acute otitis media.
    Veenhoven RH; Bogaert D; Schilder AG; Rijkers GT; Uiterwaal CS; Kiezebrink HH; van Kempen MJ; Dhooge IJ; Bruin J; Ijzerman EP; de Groot R; Kuis W; Hermans PW; Sanders EA
    Clin Infect Dis; 2004 Oct; 39(7):911-9. PubMed ID: 15472839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute otitis media due to penicillin-nonsusceptible Streptococcus pneumoniae before and after the introduction of the pneumococcal conjugate vaccine.
    McEllistrem MC; Adams JM; Patel K; Mendelsohn AB; Kaplan SL; Bradley JS; Schutze GE; Kim KS; Mason EO; Wald ER
    Clin Infect Dis; 2005 Jun; 40(12):1738-44. PubMed ID: 15909260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Conjugate pneumococcal vaccines and influence on the ear, nose and throat area].
    Almaç A; Kuru FD
    Kulak Burun Bogaz Ihtis Derg; 2011; 21(6):345-8. PubMed ID: 22014302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland.
    Blank PR; Szucs TD
    Vaccine; 2012 Jun; 30(28):4267-75. PubMed ID: 22521287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States.
    Ray GT; Pelton SI; Klugman KP; Strutton DR; Moore MR
    Vaccine; 2009 Nov; 27(47):6483-94. PubMed ID: 19720366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of using 2 vs 3 primary doses of 13-valent pneumococcal conjugate vaccine.
    Stoecker C; Hampton LM; Link-Gelles R; Messonnier ML; Zhou F; Moore MR
    Pediatrics; 2013 Aug; 132(2):e324-32. PubMed ID: 23821695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.